Creo Medical Groupは2025年第1半期の売上を倍増させ,損失を削減した一方で,EMV Capitalは開発のためにDestiny Pharmaの抗生物質資産を取得した. Creo Medical Group doubled revenue and cut losses in H1 2025, while EMV Capital acquired Destiny Pharma’s antibiotic assets for development.

Creo 医療グループは2025年度の強硬な第1回の成果を報告し,収入が50パーセント増加し220万ポンド,営業損失の43%削減,コスト削減と欧州ビジネスの大売上げの支援を図った. Creo Medical Group reported strong first-half 2025 results with a 40% revenue increase to £2.2 million and a 43% reduction in underlying operating losses, aided by cost cuts and a major sale of its European business. 株当たりGBX 4の四半期損失にもかかわらず,会社は現金準備を£20.5百万に増やし,全年収益成長予測を40〜60%再確認しました. Despite a quarterly loss of GBX 4 per share, the company boosted cash reserves to £20.5 million and reaffirmed its full-year revenue growth forecast of 40–60%. EMV Capitalは,Destiny Pharmaの抗生物質資産,XF-73鼻ゲルプラットフォームを含む,最大24億7500万ポンドで買収し,第3段階試験を進め,米国の承認を求めた. EMV Capital acquired Destiny Pharma’s antibiotic assets, including the XF-73 nasal gel platform, for up to £2.475 million, with plans to advance phase III trials and pursue U.S. approval.